Loading ...
Sorry, an error occurred while loading the content.

Mutant Flu Virus Is Found That Resists Tamiflu

Expand Messages
  • Teresa Binstock
    Notice that the standard influenza vaccine still protects , regardless of its overall pseudo-efficacy. - - - - January 31, 2008 Mutant Flu Virus Is Found That
    Message 1 of 1 , Feb 1, 2008
    • 0 Attachment
      Notice that the "standard influenza vaccine still protects", regardless
      of its overall pseudo-efficacy.

      - - - -

      January 31, 2008

      Mutant Flu Virus Is Found That Resists Popular Drug


      A small but significant percentage of the main influenza virus causing
      illness this winter in Europe, Canada and the United States has a
      mutation that makes it resistant to the anti-influenza drug Tamiflu, the
      World Health Organization said Wednesday.

      Scientists said they were surprised by the finding because they had
      believed that mutations of this type generally made the virus less
      potent and less easily spread among people. The predominant influenza
      virus circulating this winter is influenza A/H1N1. The Tamiflu-resistant
      form of the virus, known as influenza A(H1N1 H274Y), has been found with
      varying frequency in various areas of four European countries, Canada
      and the United States.

      There are no immediate plans to recommend changes in the use of Tamiflu,
      which is also known as oseltamivir, officials from the W.H.O. and the
      United States said in interviews, because the incidence of the mutant
      virus is still small. Tamiflu is one of the antiviral drugs used to
      treat influenza in its early stages.

      Nevertheless, officials from the W.H.O., a United Nations agency in
      Geneva, said they were troubled by the discovery.

      "Clearly, this is of global concern, but it is not a global problem
      now," Dr. Frederick G. Hayden, an influenza expert at the organization,
      said in a telephone interview.

      The standard influenza vaccine still protects against the mutant virus,
      said Dr. Hayden and Dr. Alicia Fry, an influenza epidemiologist at the
      Centers for Disease Control and Prevention in Atlanta.

      Norwegian epidemiologists first called attention to the problem last
      week when they reported that the mutation was present in 12 of 16, or 75
      percent, of viruses isolated in that country from patients in the
      earliest part of the influenza season, in November and December.

      The Norwegian rate was the highest among the four European countries ---
      Britain, Denmark, France and Norway --- that reported the mutant virus.
      There was no evidence that the 12 cases in Norway were linked to one

      Over all, the mutant form was found in 19 of the viruses isolated from
      148 patients or 13 percent, in a monitoring system that the European
      Center for Disease Prevention and Control runs in 10 European countries.

      The overall percentage fell to 5 if Norway was excluded.

      In the United States, the Tamiflu resistant strain was found in 9 of
      237, or 3.8 percent of patients from whom influenza type A and B viruses
      were isolated this winter, and all 9 were in the A(H1N1) category,
      making them 6.7 percent of those 135 cases, Dr. Fry, said in a telephone

      The W.H.O. conducted a teleconference lasting two hours on Tuesday to
      collect information from experts in a number of countries. The
      participants agreed that continued close monitoring was needed to
      collect information on a larger number of patients to determine the
      frequency, transmission and distribution of the mutant strain as well as
      its virulence, Dr. Hayden said.

      Scientists also want to learn how the resistance developed. It is
      unlikely to have been from use of Tamiflu, Dr. Hayden said, in part
      because no cases have been detected in Japan, where the drug is often
      used in treatment.


      The material in this post is distributed without
      profit to those who have expressed a prior interest
      in receiving the included information for research
      and educational purposes.For more information go to:
      If you wish to use copyrighted material from this
      email for purposes that go beyond 'fair use', you
      must obtain permission from the copyright owner*.*

      [Non-text portions of this message have been removed]
    Your message has been successfully submitted and would be delivered to recipients shortly.